TROGARZO

This brand name is authorized in United States. It is also authorized in Austria, Estonia, Ireland, Israel, Lithuania, Poland.

Active ingredients

The drug TROGARZO contains one active pharmaceutical ingredient (API):

1	Ibalizumab UNII LT369U66CE - IBALIZUMAB
	Ibalizumab, a humanized monoclonal antibody of immunoglobulin G type 4 (IgG4), is a CD4 domain 2-directed HIV-1 inhibitor. Ibalizumab blocks HIV-1 from infecting CD4+ T cells by binding to domain 2 of CD4 and interfering with the post-attachment steps required for the entry of HIV-1 virus particles into host cells and preventing the viral transmission that occurs via cell-cell fusion.
	Read more about Ibalizumab

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
TROGARZO Solution for injection	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J05AX23		J Antiinfectives for systemic use → J05 Antivirals for systemic use → J05A Direct acting antivirals → J05AX Other antivirals
Discover more medicines within J05AX23

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1802359
IL	מִשְׂרַד הַבְּרִיאוּת	8794
LT	Valstybinė vaistų kontrolės tarnyba	1088560
PL	Rejestru Produktów Leczniczych	100427238
US	FDA, National Drug Code	62064-122